ABSTRACT Breast cancer is second leading cause of cancer deaths among women. In India, total 5lacs breast cancer patients are found with annual increment of 1.25lacs. Human Leukocyte Antigen (HLA) has been reported to be an interesting tool for predisposition and protection of breast cancer. Association of ethnicity specific HLA allele haplotypes has a significant role in increased risk of breast cancer. Our aim was to find out correlation of different HLA class I & II alleles and susceptible and probable alleles associated with breast cancer in eastern Indian population, to make women having susceptible HLA subtypes, aware to prevent breast cancer by lifestyle modification or by detecting at an early stage. Till now 21 patients along with 18 normal controls were studied for both HLA Class-I & Class-II loci. Blood samples were collected and genomic DNA was isolated. Low resolution molecular typing using PCR-based sequence-specific primer technique and allele assignment were performed to detect HLA-A, B, C and HLA-DRB1, DQB1 alleles. HLA-A frequencies between both case and control groups showed no difference from the statistical viewpoint. HLA-B*1501 was found three times more common in the case groups. Probably HLA-C*7 has a protective role for the disease as it was expressed in 66% in normal control, but only 14% in patients. Although DRB1*15 were reported to be susceptible to other ethnic population, we found no significant difference between cases and control. Probably DQB1*05-allele expression has a protective role in our population. The number of individuals as well as control was too small to confirm the susceptible or probable alleles associated with breast cancer. But our results revealed the role of the MHC genes in the patho-physiology of breast cancer, suggesting a disorder of immune regulation. Close follow-up and monitoring will help us to interpret statistically high-risk group of breast cancer patients which will reduce the breast cancer burden in the community. Disclosure All authors have declared no conflicts of interest.